Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 08.05.2026 IPXE.IM IE00BFD26097 50,002.00 EUR 1,261,034.03 25.220  ...

東京--(BUSINESS WIRE)--(美國商業資訊)-- 由株式會社Kakaku.com經營的日本最大級（※1）餐廳搜尋與訂位服務「Tabelog（https://tabelog.com/en/）」所推出之訪日旅客專用多語版App（iOS/Android），自上線約六個月內即突破200萬次下載（※2）。 此外，於台灣、香港、韓國及美國之「訪日旅客使用的日本美食搜尋App」下載排行榜中亦榮獲第一名（※3），深受全球旅客支持。 下載連結： https://tabelog-tourists.onelink.me/3eEh/iqkkho9r 深受全球旅客喜愛的理由——改善日本旅行中的兩大不便 造訪日本的旅客在用餐方面長期面臨兩大主要障礙。 【課題1】資訊落差：多為面向觀光客的資訊，難以找到在地人實際常去的餐廳 【課題2】語言隔閡:不熟悉日文時，難以透過電話完成訂位，可能因此錯過心儀餐廳 Tabelog 多語版App針對上述兩項課題提供解決方案。透過日本用戶累積的真實評論與照片，讓旅客更容易發掘「在地人常去的餐廳」，此一特點深受訪日旅客肯定。同時，App支援英文、繁體中文以及韓文的手機線上...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 08.05.2026 CPQ IE00BFD2H405 6,825,002.00 USD 372,584,393.74 54.591  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 08.05.2026 FDNU IE00BG0SSC32 1,225,002.00 USD 45,272,456.57 36.957  ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through science and technology.” The new Five-Year Business Plan reinforces the enduring purpose of Daiichi San...

AMSTERDAM--(BUSINESS WIRE)--AM Best has maintained its stable outlook on Italy's non-life insurance segment and expects gross written premium (GWP) in the segment to continue on a steady growth trend during 2026 across all lines of business, although at a slower pace than in recent years. In its new Best’s Market Segment Report, “Market Segment Outlook: Italy Non-Life Insurance”, AM Best also states that the additional fiscal burden from the 2026 Budget Law will not place significant pressure o...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD)(Euronext Compartiment B – ISIN : FR001400AHX6), société spécialisée dans le diagnostic in vitro, annonce aujourd'hui ses résultats annuels pour l'exercice clos le 31 décembre 2025, arrêtés par le Conseil d'administration lors de sa réunion du 30 avril 2026. Indicateur financier Exercice 2025 Exercice 2024 Variation (%) Chiffre d'affaires 6 950 k€ 5 330 k€ + 30,4 % Résultat opérationnel 290 k€ - 490 k€ + 159,2 % Résul...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD)(Euronext Compartment B – ISIN: FR001400AHX6), a company specialized in in vitro diagnostics, today announces its annual results for the fiscal year ended December 31, 2025, approved by the Board of Directors during its meeting on April 30, 2026. Financial Indicator FY 2025 FY 2024 Change (%) Revenue €6,950k €5,330k +30.4% Operating Result €290k -€490k +159.2% Net Income €987k €285k +246.0% Cash-Flow from Operations €...

LITTLETON, Mass.--(BUSINESS WIRE)--Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatm...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: This press release and the information it contains must not be distributed, directly or indirectly, in the United States, Canada, Japan or Australia. Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a robotic platform for non‑invasive therapy using high‑intensity focused ultrasound (HIFU) for the treatment of varicose veins (the “Company”), announces the strong success of its € 5,992,544.16 capital increase with...